Exact Sciences Announces Second Quarter 2022 Results
Second quarter highlights Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154...
Source: prnewswire.com
📰 Recurrence Score News
Page 4 - Recurrence Score News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recurrence Score. Real-time updates on events, politics, business and more.
Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with...
Source: prnewswire.com
Agendia, Inc.: Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrint is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions
Source: finanznachrichten.de
Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and...
Source: prnewswire.co.uk
Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and...
Source: prnewswire.com
Breast Cancer Test Recommended for Extended Endocrine Therapy
The Breast Cancer Index is the only genomic test that should be used to guide extended endocrine therapy decisions for women with early-stage, hormone receptor–positive breast cancer, says ASCO.
United States Mark Pegram National Surgical Adjuvant Breast American Society Of Clinical Oncology American Society Clinical Oncology
Source: medscape.com
Oncolytics Biotech Inc.: Oncolytics Biotech and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant
Source: finanznachrichten.de
Financialnewsmedia.com: HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
PALM BEACH, Fla., May 4, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over
Source: finanznachrichten.de
EXACT SCIENCES CORP: Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Oncotype DX receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent
Source: finanznachrichten.de
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast...
Rick Baehner Exchange Commission Sciences Corp Sciences On Facebook Genomic Health Inc Precision Oncology At Exact Sciences
Source: prnewswire.co.uk